Compare Regeneron Pharmaceuticals Inc (REGN) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Invesco Solar ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Invesco Solar ETF trades at $44.19 (market cap $911.39M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 83.8× Invesco Solar ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Invesco Solar ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Invesco Solar ETF for 34 Days on average.
| REGN | TAN | |
|---|---|---|
Market Cap | $76.40B | $911.39M |
Volume | 626,381 | 983,074 |
Sector | Health | Sector/Thematic |
52-Week High | $852.03 | $73.95 |
52-Week Low | $557.73 | $43.00 |
Typical Hold Time | 107 Days | 34 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
TAN (Invesco Solar ETF) trades at $43.53, down 1.96% amid sector-wide pressure from high borrowing costs impacting solar project financing. Technical indicators show a bearish trend with strong sell signals from moving averages, while oscillators remain neutral. Recent news highlights solar stocks facing headwinds from interest rate sensitivity and market saturation concerns, though long-term growth drivers from energy transition remain intact.
The ETF faces near-term challenges from financing costs and competitive pressures, but maintains strategic positioning in the growing solar energy sector. Investors should weigh volatility risks against potential policy tailwinds and increasing global renewable energy adoption for long-term growth opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
